---
doc_id: LD-05
title: "Microbiology and Infection Diagnostics Reports"
folder: 04_Laboratory_Diagnostics
version: 1.0
created: 2026-10-01
synthetic: true
entities: [PAT-003, PAT-006, PAT-009, PAT-013, LAB-012, LAB-013, LAB-024, PRO-009, DEP-011, DEP-013, STF-012, ALG-001, ALG-006, INC-004, FPA-13]
related_docs: [DG-05, HO-04, HO-05, HO-06, HO-08, LD-01, MP-04, MP-07, PR-03, PR-06, PR-07, PR-08]
---

# LD-05: Microbiology and Infection Diagnostics Reports

> **SYNTHETIC DATA NOTICE.** MediCore Hospital and every patient, organism, susceptibility, and report number in this document are fictional. The reports exist only for software benchmarking and education and must not be used for clinical decisions.

## 1. Document Control

| Field | Value |
|---|---|
| Document ID | LD-05 |
| Folder | 04_Laboratory_Diagnostics |
| Version / date | 1.0 / 2026-10-01 |
| Performing department | Clinical Laboratory (DEP-011); verified under STF-012 |
| Tests | LAB-012 blood culture with susceptibility, LAB-013 urinalysis and urine culture, LAB-024 C. difficile toxin/PCR |
| Reference and critical rules | LD-01: any positive blood culture bottle and any positive C. difficile result are PRO-009 critical results, phoned within 20 minutes of verification (FPA-13) |
| Related documents | PR-03, PR-06, PR-07, PR-08; DG-05; MP-04; HO-04, HO-06 |

## 2. Purpose and Scope

Report series for four patients. Susceptibility interpretation uses fictional MediCore breakpoints; S = susceptible, R = resistant.

## 3. PAT-003 (Thomas Okonkwo-Reyes), 2026-02-26 to 2026-03-07

### 3.1 Blood cultures (LAB-012)

| Report | Time (2026) | Result |
|---|---|---|
| RPT-LD05-001 | 02-26 10:25 | Two sets collected before the first antibiotic (ceftriaxone given 10:58) |
| RPT-LD05-002 | 02-27 04:10 | Aerobic bottle positive: **gram-positive cocci in chains** (critical; phoned 04:18) |
| RPT-LD05-003 | 02-28 09:30 | Identification: **Streptococcus pneumoniae** in both sets |
| RPT-LD05-004 | 03-01 08:20 | Susceptibilities: **penicillin S; ceftriaxone S; vancomycin S**; erythromycin R |

The stewardship decision to de-escalate was taken at 13:00 on 2026-03-01, 4 hours 40 minutes after this report (PR-03, HO-04).

### 3.2 C. difficile toxin/PCR (LAB-024)

| Report | Time (2026) | Result |
|---|---|---|
| RPT-LD05-005 | 03-06 22:10 | Stool received after onset of watery diarrhea that evening |
| RPT-LD05-006 | **03-07 08:40** | **Toxin gene PCR positive; toxin EIA positive.** Critical result; phoned to the ward nurse at **08:52** (12 minutes after verification) |
| RPT-LD05-007 | 03-07 14:50 | Infection Prevention (DEP-013) notified by the ward charge nurse |

Contact-enteric precautions started at **15:25** on 2026-03-07, 6 hours 45 minutes after verification (INC-004; PR-03, HO-06, HO-08). The laboratory's own call was within the 20-minute policy; the delay occurred after the call.

## 4. PAT-006 (Grace Lindqvist-Obi), 2025-10-21 to 2025-11-04

| Report | Time | Test | Result |
|---|---|---|---|
| RPT-LD05-008 | 2025-10-21 17:05 | Urinalysis (LAB-013) | Nitrite **positive**; leukocyte esterase **3+**; blood trace |
| RPT-LD05-009 | 2025-10-23 | Urine culture | **Escherichia coli, more than 10^5 CFU/mL**. Susceptible: **ciprofloxacin, ceftriaxone**, amoxicillin-clavulanate. Resistant: **ampicillin** |
| RPT-LD05-010 | 2025-11-04 | Repeat urine culture | **No growth** |

Susceptibility to amoxicillin-clavulanate was reported but the drug was not used because of penicillin allergy ALG-001 (MP-07). Ciprofloxacin was chosen and later stopped for the warfarin interaction (PR-06).

## 5. PAT-009 (Lucia Fernandes-Adler), 2026-03-22

| Report | Time | Test | Result |
|---|---|---|---|
| RPT-LD05-011 | 2026-03-22 | Urinalysis (LAB-013) | Nitrite **positive**; leukocyte esterase **3+**; protein 1+ |
| RPT-LD05-012 | 2026-03-24 | Urine culture | **Escherichia coli, more than 10^5 CFU/mL**; ceftriaxone **S** |

Ceftriaxone 1 g IV daily was started on 2026-03-22 and continued for 7 days (PR-07). A latex-free catheter was used because of ALG-006.

## 6. PAT-013 (Daniel Oyelaran-Whitfield), 2026-06-18 to 2026-06-21

| Report | Time (2026) | Test | Result |
|---|---|---|---|
| RPT-LD05-013 | 06-18 04:25 | Blood cultures and urine culture | Collected before piperacillin-tazobactam (given 04:52) |
| RPT-LD05-014 | 06-19 09:00 | Urine culture preliminary | Gram-negative bacilli more than 10^5 CFU/mL |
| RPT-LD05-015 | 06-19 14:30 | Blood culture bottle positive | **Gram-negative bacilli**; critical; phoned 14:41 (11 minutes) |
| RPT-LD05-016 | 06-20 09:10 | Identification | **Escherichia coli** in blood and urine |
| RPT-LD05-017 | 06-21 10:00 | Susceptibilities | **Piperacillin-tazobactam S; ceftriaxone S; ESBL negative** |

IV vancomycin was stopped at 12:00 on 2026-06-20 once only gram-negative organisms were identified (PR-08, HO-04). Ceftriaxone began on 2026-06-21.

## 7. Cross-Reference Table

| Topic | Where to verify |
|---|---|
| Critical value rules | LD-01, HO-05 |
| Sepsis, UTI and C. difficile treatment | DG-05 |
| Antibiotic monographs | MP-04 |
| Stewardship protocol | HO-04 |
| Isolation precautions | HO-06 |
| Incident review (INC-004) | HO-08 |
| Patient charts | PR-03, PR-06, PR-07, PR-08 |

## 8. Document Change Log

| Version | Date | Change |
|---|---|---|
| 1.0 | 2026-10-01 | Initial synthetic report series (Pass 1) |
